Skip to main content
Fig. 5 | BMC Medical Informatics and Decision Making

Fig. 5

From: Workflow-driven clinical decision support for personalized oncology

Fig. 5

Details of two simulated bevacizumab monotherapy schemes (dosage, frequency of administration and timepoints of administration). The treatment scheme details are extracted from European medicines agency (Avastin, INN - bevacizumab - WC500029271.pdf) and constitute the two suggested modes of bevacizumab administration for metastatic breast cancer

Back to article page